MedTrace Logo

The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)

NCT00815373 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-03-16

No results posted yet for this study

Summary

Both Cosopt® and Xalatan® plus Timoptic® will significantly lower IOP, however only Cosopt® will demonstrate positive hemodynamic effects. The clinical significance of this will be investigated by examining the ophthalmic and short posterior ciliary arteries to determine the blood supply to the optic nerve head, the site of damage in glaucoma

Conditions

Interventions

DRUG

Dorzolamide+Timolol Maleate0.5%

Cosopt\* b. i. d.

DRUG

Latanoprost+Timolol Maleate0.5%+Lytears

Xalacom\* QHS

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Adi Abulafia, MD · Meir Medical Center, Tel Aviv University

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-12-31
Completion
2012-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815373 on ClinicalTrials.gov